Stefan Aebi
Stefan Aebi
Medical Oncology, Cancer Center Lucerne Cantonal Hospital, and University of Berne
Verified email at - Homepage
Cited by
Cited by
The role of DNA mismatch repair in platinum drug resistance
D Fink, S Nebel, S Aebi, H Zheng, B Cenni, A Nehmé, RD Christen, ...
Cancer research 56 (21), 4881-4886, 1996
The role of DNA mismatch repair in drug resistance.
D Fink, S Aebi, SB Howell
Clinical cancer research: an official journal of the American Association …, 1998
Loss of DNA mismatch repair in acquired resistance to cisplatin
S Aebi, B Kurdi-Haidar, R Gordon, B Cenni, H Zheng, D Fink, RD Christen, ...
Cancer Research 56 (13), 3087-3090, 1996
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
HJ Burstein, G Curigliano, B Thürlimann, WP Weber, P Poortmans, ...
Annals of Oncology 32 (10), 1216-1235, 2021
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Aebi, T Davidson, G Gruber, F Cardoso, ...
Annals of oncology 22 (suppl 6), vi12-vi24, 2011
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
S Aebi, S Gelber, M Castiglione-Gertsch, RD Gelber, J Collins, ...
The Lancet 355 (9218), 1869-1874, 2000
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
D Fink, H Zheng, S Nebel, PS Norris, S Aebi, TP Lin, A Nehmé, ...
Cancer research 57 (10), 1841-1845, 1997
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
F Cardoso, JMS Bartlett, L Slaets, CHM van Deurzen, ...
Annals of Oncology 29 (2), 405-417, 2018
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93
International Breast Cancer Study Group
Journal of Clinical Oncology 24 (9), 1332-1341, 2006
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
S Aebi, D Fink, R Gordon, HK Kim, H Zheng, JL Fink, SB Howell
Clinical cancer research: an official journal of the American Association …, 1997
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
S Aebi, S Gelber, SJ Anderson, I Láng, A Robidoux, M Martín, ...
The Lancet Oncology 15 (2), 156-163, 2014
The Notch pathway in ovarian carcinomas and adenomas
O Hopfer, D Zwahlen, MF Fey, S Aebi
British journal of cancer 93 (6), 709-718, 2005
First international consensus guidelines for breast cancer in young women (BCY1)
AH Partridge, O Pagani, O Abulkhair, S Aebi, F Amant, HA Azim Jr, ...
The Breast 23 (3), 209-220, 2014
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Aebi, T Davidson, G Gruber, M Castiglione, ...
Annals of oncology 21 (suppl 5), v9-v14, 2010
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and-deficient cells exposed to cisplatin
A Nehmé, R Baskaran, S Aebi, D Fink, S Nebel, B Cenni, JYJ Wang, ...
Cancer research 57 (15), 3253-3257, 1997
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib
O Gautschi, C Pauli, K Strobel, A Hirschmann, G Printzen, S Aebi, ...
Journal of Thoracic Oncology 7 (10), e23-e24, 2012
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
U Amstutz, S Farese, S Aebi, CR Largiadèr
Pharmacogenomics 10 (6), 931-944, 2009
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity
TK Froehlich, U Amstutz, S Aebi, M Joerger, CR Largiadèr
International journal of cancer 136 (3), 730-739, 2015
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
A Keshaviah, S Dellapasqua, N Rotmensz, J Lindtner, D Crivellari, ...
Annals of oncology 18 (4), 701-708, 2007
Assessment of differences in patient populations selected for or excluded from participation in clinical phase III acute myelogenous leukemia trials
C Mengis, S Aebi, A Tobler, W Dähler, MF Fey
Journal of clinical oncology 21 (21), 3933-3939, 2003
The system can't perform the operation now. Try again later.
Articles 1–20